Disease on EC 1.1.1.34 - hydroxymethylglutaryl-CoA reductase (NADPH)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death.
Acquired Immunodeficiency Syndrome
Endogenous sodium potassium ATPase inhibition related biochemical cascade and the acquired immunodeficiency syndrome--neural regulation of viral replication and immune response to the virus.
Hypothalamic digoxin, hemispheric dominance and the acquired immunodeficiency syndrome.
Acute Coronary Syndrome
Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
Defining the role of high-dose statins in PCI.
Early statin initiation and outcomes in patients with acute coronary syndromes.
Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction.
Early use of statins in acute coronary syndromes.
Effect on Short- and Long-Term Major Adverse Cardiac Events of Statin Treatment in Patients With Acute Myocardial Infarction and Renal Dysfunction.
HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats.
How aggressive should lipid lowering be among patients with acute coronary syndromes?
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.
Lipids and stroke: the opportunity of lipid-lowering treatment.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Statin withdrawal: clinical implications and molecular mechanisms.
T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents?
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Utility of early high dose statins in acute coronary syndrome.
[Oxidized low-density lipoprotein enhances the expressions of SREBP-2 and HMGCR mRNA in macrophages derived from the monocytes of patients with acute coronary syndrome]
[Statins in the management of acute coronary syndrome]
Acute Kidney Injury
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
HMG-CoA Reductase Activation and Urinary Pellet Cholesterol Elevations in Acute Kidney Injury.
Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine.
Renal ischemia-induced cholesterol loading: transcription factor recruitment and chromatin remodeling along the HMG CoA reductase gene.
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor.
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
Acute Lung Injury
Long-term Simvastatin Administration Attenuates Lung Injury and Oxidative Stress in Murine Acute Lung Injury Models Induced by Oleic Acid and Endotoxin.
Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury.
Adenocarcinoma
3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors.
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.
Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA.
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
Adenocarcinoma, Bronchiolo-Alveolar
Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
Adenoma
Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas.
Adrenoleukodystrophy
X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism.
Albuminuria
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Insulin Resistance, Oxidative Stress, and Podocyte Injury: Role of Rosuvastatin Modulation of Filtration Barrier Injury.
Alveolitis, Extrinsic Allergic
Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
Alzheimer Disease
A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations.
Association between statin use and Alzheimer's disease.
Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese.
Atorvastatin ameliorates cognitive impairment, A?1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.
Atorvastatin stimulates neuroblastoma cells to induce neurite outgrowth by increasing cellular prion protein expression.
Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
Can statins put the brakes on Alzheimer's disease?
Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease.
Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.
Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.
Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's disease suggests a role for rs3846662 and HMGCR splicing in disease risk.
High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs.
HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.
HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.
Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk.
Mechanisms of statin-mediated inhibition of small G-protein function.
Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins.
Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease.
Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimer's Disease.
Simvastatin inhibits protein isoprenylation in the brain.
Statins and neuroprotection: a prescription to move the field forward.
Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism.
Therapeutic approaches to the treatment of Alzheimer's disease.
[Direct neuronal effects of statins]
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.
Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.
Anemia, Hypochromic
Overexpression of farnesyl diphosphate synthase in Arabidopsis mitochondria triggers light-dependent lesion formation and alters cytokinin homeostasis.
Aneurysm
A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).
Medical management of small abdominal aortic aneurysms.
Angina Pectoris
Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography.
Angina, Stable
Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Angina, Unstable
Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering.
[Statins decreases expression of five inflammation-associated microRNAs in the plasma of patients with unstable angina].
Aortic Aneurysm, Abdominal
A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.
A Randomised Placebo-controlled Double-blind Trial to Evaluate Lipid-lowering Pharmacotherapy on Proteolysis and Inflammation in Abdominal Aortic Aneurysms.
HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms.
Aortic Valve Stenosis
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).
Arterial Occlusive Diseases
Peripheral arterial disease: a review of disease awareness and management.
Arteriosclerosis
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
HMG-CoA reductase inhibitors in organ transplantation.
Arteritis
Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women.
Arthritis, Experimental
Effects of pravastatin in murine collagen-induced arthritis.
Arthritis, Rheumatoid
Bone protective effect of simvastatin in experimental arthritis.
Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis.
HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients.
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.
Aspergillosis, Allergic Bronchopulmonary
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Asthma
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Statin Exposure is Associated with Decreased Asthma-Related Emergency Department Visits and Oral Corticosteroid Use.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
[Simvastatin induces eosinophil apoptosis in vitro]
Atherosclerosis
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA.
A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.
A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits.
Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells.
Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
An in vitro method using vascular smooth muscle cells to study the effect of compounds on cell proliferation and intracellular lipid accumulation.
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease.
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins.
Biological knowledge-driven analysis of epistasis in human GWAS with application to lipid traits.
CE: Triglycerides: Do They Matter?
Clinical evidence for Japanese population based on prospective studies-Linking clinical trials and clinical practice.
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Comparative tolerability of the HMG-CoA reductase inhibitors.
Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Coronary Plaque Burden at Coronary CT Angiography in Asymptomatic Men and Women.
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.
Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.
Diabetes mellitus-associated atherosclerosis : mechanisms involved and potential for pharmacological invention.
Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system.
Drug Insight: using statins to treat neuroinflammatory disease.
Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits.
Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients.
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells.
Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene.
Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery.
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro.
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals.
Effects of statins on adhesion molecule expression in endothelial cells.
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
Genomic analysis of circulating cells: a window into atherosclerosis.
HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis.
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
HMG-CoA reductase inhibitors: a look back and a look ahead.
HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol.
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice.
Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
In vitro screening for ?-hydroxy-?-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk.
Influence of statins on MHC class I expression.
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Knowledge-driven analysis identifies a gene-gene interaction affecting high-density lipoprotein cholesterol levels in multi-ethnic populations.
L-arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix.
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
Low-dose cerivastatin inhibits spontaneous atherogenesis in heterozygous watanabe hyper lipidemic rabbits.
Lycopene regulation of cholesterol synthesis and efflux in human macrophages.
Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations.
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Molecular mechanisms underlying the onset of degenerative aortic valve disease.
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Optimizing cardiovascular outcomes in diabetes mellitus.
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo.
Pleiotropic effects of HMG-CoA reductase inhibitors.
Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase.
Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine.
Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Proteomic analysis of endothelial cell secretome: a means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors.
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects).
Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol.
Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors.
Rosuvastatin Improves Endothelial Function of db/db Mice: Role of Angiotensin II Type 1 Receptors and Oxidative Stress.
Rosuvastatin: a review of its effect on atherosclerosis.
Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
Simvastatin Increases ADAMTS13 Expression in Podocytes.
Simvastatin inhibited oxLDL-induced proatherogenic effects through calpain-1-PPAR?-CD36 pathway.
Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA.
Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.
Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.
Statin treatment and progression of atherosclerotic plaque burden.
Statin-stimulated nitric oxide release from endothelium.
Statins and demyelination.
Statins in the treatment of central nervous system autoimmune disease.
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes.
Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS).
The effect of statins on postprandial lipemia.
The effects of HMG-CoA reductase inhibitor on vascular progenitor cells.
The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis.
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
The pathology of atherosclerosis: plaque development and plaque responses to medical treatment.
The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Torcetrapib + atorvastatin (Pfizer).
Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Use of Statins for Secondary Prevention.
Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin.
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
[Anti-atherosclerotic actions of HMG-CoA reductase inhibitors]
[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk]
[Fluvastatin in the treatment of hyperlipoproteinemia, initial experience]
[Pleiotropic effects of statins]
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis]
Atrial Fibrillation
Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin?
Fluvastatin Reduces Pulmonary Vein Spontaneous Activity Through Nitric Oxide Pathway.
Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
Post-cardiothoracic surgery atrial fibrillation: a review of preventive strategies.
Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery.
Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Simvastatin attenuates sympathetic hyperinnervation to prevent atrial fibrillation during post-myocardial infarction remodeling process.
Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Targeting inflammation and oxidative stress in atrial fibrillation: Role of HMG-CoA reductase inhibition with statins.
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
The role of statins in cancer therapy.
Autoimmune Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Bacteremia
The role of statin therapy in sepsis.
Bacterial Infections
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.
Blister
3-hydroxy-3-methyl glutaryl coenzyme A reductase: an essential actor in the biosynthesis of cantharidin in the blister beetle Epicauta chinensis Laporte.
Bone Resorption
Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly.
Bone protective effect of simvastatin in experimental arthritis.
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Brain Injuries
HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons.
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: A translational approach.
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Brain Injuries, Traumatic
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury.
Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.
Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
Statins and neuroprotection: a prescription to move the field forward.
Brain Ischemia
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Alterations of interneurons of the gerbil hippocampus after transient cerebral ischemia: effect of pitavastatin.
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]
Brain Neoplasms
3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors.
Breast Neoplasms
17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation.
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.
Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins.
Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development.
Dysregulation of the mevalonate pathway promotes transformation.
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Efficient Use of Exogenous Isoprenols for Protein Isoprenylation by MDA-MB-231 Cells Is Regulated Independently of the Mevalonate Pathway.
Factors released from human breast-cancer cells counteract the inhibitory effects of mevinolin on DNA-synthesis and morphology but not on hmg coa reductase-activity.
Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Increased 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in a virilizing adrenal carcinoma.
Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell.
Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.
MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.
Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds.
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells.
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.
Regulatory role of mevalonate in the growth of normal and neoplastic human mammary epithelial cells.
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Statins and cancer development.
Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region.
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
Breast Neoplasms, Male
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
Bronchitis, Chronic
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Carcinogenesis
A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis.
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-Kras(G12D) -LSL-Trp53(R172H) -Pdx1-Cre mice.
Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.
Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice.
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models.
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells.
Hypolipidemic effect of ginger in 1,2-dimethyl hydrazine-induced experimental colon carcinogenesis.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.
Regulation of mevalonate synthesis in low density lipoprotein receptor knockout mice fed n-3 or n-6 polyunsaturated fatty acids.
Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases.
Carcinoma
3-Hydroxy-3-methylglutaryl coenzyme a reductase activity in liver of athymic mice with or without an implanted human carcinoma.
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human adrenal cortex.
Diosgenin, a naturally occurring furostanol saponin suppresses 3-hydroxy-3-methylglutaryl CoA reductase expression and induces apoptosis in HCT-116 human colon carcinoma cells.
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo.
Increased 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in a virilizing adrenal carcinoma.
Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell.
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
Synergistic Impact of d-?-Tocotrienol and Geranylgeraniol on the Growth and HMG CoA Reductase of Human DU145 Prostate Carcinoma Cells.
Carcinoma, Acinar Cell
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Carcinoma, Hepatocellular
A sensitive RNase protection assay for the quantitation of the mRNAs for the LDL receptor and HMG-CoA reductase in human total RNA. Effects of treatments on cells in culture designed to up- and down-regulate expression of the LDL receptor.
Activation of AMP-kinase by Policosanol Requires Peroxisomal Metabolism.
Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors.
An improved assay of 3-hydroxy-3-methylglutaryl-CoA reductase activity in Reuber H35 hepatoma cells without microsomes isolation.
Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase.
Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor.
Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular Carcinoma.
Chlamydia trachomatis growth inhibition and restoration of LDL-receptor level in HepG2 cells treated with mevastatin.
Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Comparison of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma cells grown in vivo and in vitro.
Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels.
Differential regulation of hepatic triglyceride lipase and 3-hydroxy-3-methylglutaryl-CoA reductase gene expression in a human hepatoma cell line, HepG2.
Differential translational effects of myristic acid and eicosapentaenoic acid on 3-hydroxy-3-methylglutaryl-CoA reductase from Reuber H35 hepatoma cells.
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Effect of ketoconazole on cholesterol synthesis and on HMG-CoA reductase and LDL-receptor activities in Hep G2 cells.
Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway.
Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2.
Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells.
Growth-rate-related and hydroxysterol-induced changes in membrane fluidity of cultured hepatoma cells: correlation with 3-hydroxy-3-methyl glutaryl CoA reductase activity.
Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids.
Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis.
Identification of insulin-responsive regions in the HMG-CoA reductase promoter.
Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis.
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in hepatoma tissue culture cells by pure cholesterol and several cholesterol derivatives. Evidence supporting two distinct mechanisms.20l.
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid.
Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid levels.
Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation.
Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells.
MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1.
Modification of phospholipids fatty acid composition in reuber H35 hepatoma cells: effect on HMG-CoA reductase activity.
MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase.
NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells.
Partial "feedback control" of beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity in primary hepatocellular carcinomas.
Phosphorylation of hepatic AMP-activated protein kinase and liver kinase B1 is increased after a single oral dose of green tea extract to mice.
Plasma membrane sphingomyelin and the regulation of HMG-CoA reductase activity and cholesterol biosynthesis in cell cultures.
Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase.
Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Properties of 3-hydroxy-3-methylglutaryl coenzyme A reductase solubilized from rat liver and hepatoma.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma tissue culture cells by serum lipoproteins.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase in minimal deviation hepatoma 7288C. Immunological measurements in hepatoma tissue culture cells.
Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites.
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in human hepatoma cell line Hep G2. Effects of inhibitors of cholesterol synthesis on enzyme activity.
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in rat liver and Morris hepatomas 5123C, 9618A and 5123t.c.
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol.
Regulation of the Lactobacillus Strains on HMGCoA Reductase Gene Transcription in Human HepG2 Cells via Nuclear Factor-?B.
Regulation of the rate of sterol synthesis and the level of beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity in mouse liver and hepatomas.
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Reversible phosphorylation of 3-hydroxy-3-methylglutaryl CoA reductase in Morris hepatomas.
RHOA is a modulator of the cholesterol-lowering effects of statin.
Robinetinidol-flavone attenuates cholesterol synthesis in hepatoma cells via inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Role of mevalonate in regulation of cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured cells and their cytoplasts.
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
Statins increase cytochrome P450 4F3-mediated eicosanoids production in human liver cells: A PXR dependent mechanism.
Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas.
SUGP1 is a novel regulator of cholesterol metabolism.
Supernatant protein factor requires phosphorylation and interaction with Golgi to stimulate cholesterol synthesis in hepatoma cells.
Suppression of rat liver tumorigenesis by 25-hydroxycholesterol and all-trans retinoic acid: differentiation therapy for hepatocellular carcinoma.
Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.
The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2.
The effect of 25-hydroxycholesterol on the regulation of apolipoprotein E mRNA levels and secretion in the human hepatoma HepG2.
The regulation of beta-hydroxy-beta-methylglutaryl coenzyme A reductase in Morris hepatomas 5123C, 7800, and 9618A.
Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts.
[Affinity of 3-beta-(2-hydroxyethoxy)-5-alpha-cholest-8(14)-ene-15-one to oxysterol binding protein and its metabolism in HepG2 hepatoma cells]
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellar carcinoma].
Carcinoma, Intraductal, Noninfiltrating
The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Carcinoma, Mucoepidermoid
Simvastatin effects on a human lung carcinoma and cholesterol homeostasis of host and non-host mice.
Carcinoma, Renal Cell
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Carcinoma, Squamous Cell
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Cardiomegaly
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Involvement of peptidyl-prolyl isomerase Pin1 in the inhibitory effect of fluvastatin on endothelin-1-induced cardiomyocyte hypertrophy.
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Matrix Metalloproteinase-2 Mediates a Mechanism of Metabolic Cardioprotection Consisting of Negative Regulation of the Sterol Regulatory Element-Binding Protein-2/3-Hydroxy-3-Methylglutaryl-CoA Reductase Pathway in the Heart.
Regulation of phospholamban and sarcoplasmic reticulum Ca2+-ATPase by atorvastatin: implication for cardiac hypertrophy.
Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors.
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes.
Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway.
Statin therapy for cardiac hypertrophy and heart failure.
Statins and the myocardium.
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
[Simvastatin attenuates cardiovascular effects and oxidative stress induced by angiotensin II]
Cardiomyopathies
Inflammation in chronic heart failure.
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Cardiomyopathy, Hypertrophic
HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Cardiotoxicity
Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors.
Cardiovascular Diseases
3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.
A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats.
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis.
A Review on the use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis.
Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules.
Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions.
Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?: A Retrospective Cohort Study.
Association of race with cumulative exposure to statins in dialysis.
Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression.
Bone protective effect of simvastatin in experimental arthritis.
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors.
CE: Triglycerides: Do They Matter?
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
Clinical implications of pharmacogenetic variation on the effects of statins.
Combination Therapy of Amlodipine and Atorvastatin Has More Beneficial Vascular Effects Than Monotherapy in Salt-Sensitive Hypertension.
Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis.
Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.
Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).
Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Direct vascular effects of HMG-CoA reductase inhibitors.
Dyslipidemia in older adults.
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit.
Effect of monthly atorvastatin treatment on hemostasis.
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells.
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
Identification of novel inhibitors of dietary lipid absorption using zebrafish.
Implications of recent statin trials for primary care practice.
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors.
Lipid lowering in liver and chronic kidney disease.
Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges.
Management of the Metabolic Syndrome and the Obese Patient with Metabolic Disturbances: South Asian Perspective.
Molecular mechanisms underlying the effects of statins in the central nervous system.
Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases.
Neuroprotective Effect of Simvastatin via Inducing the Autophagy on Spinal Cord Injury in the Rat Model.
On- and Off-Target Pharmacology of Torcetrapib: Current Understanding and Implications for the Structure Activity Relationships (SAR), Discovery and Development of Cholesteryl Ester-Transfer Protein (CETP) Inhibitors.
Optimal therapy of low levels of high density lipoprotein-cholesterol.
Optimizing cardiovascular outcomes in diabetes mellitus.
Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.
Pleiotropic effects of HMG-CoA reductase inhibitors.
Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin.
Pleiotropic effects of statins on the treatment of chronic periodontitis - a systematic review.
Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase.
Potential role of statin therapy in heart failure, atrial fibrillation and aortic stenosis.
Potential therapeutic role of statins in neurological disorders.
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease.
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Regulation of lipid metabolism in chicken liver by dietary cereals.
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Role of bile acid sequestrants in the treatment of type 2 diabetes.
Role of C-reactive protein in cardiovascular disease.
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders : Progress to Date.
Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field.
Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice.
Simvastatin inhibits catecholamine secretion and synthesis induced by acetylcholine via blocking Na+ and Ca2+ influx in bovine adrenal medullary cells.
Simvastatin modulates remodeling of Kv4.3 expression in rat hypertrophied cardiomyocytes.
Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling.
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
Statin mediated protection of the ischemic myocardium.
Statin therapy and myocardial no-reflow.
Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?
Statin use and breast cancer: do we need more evidence and what should this be?
Statin Use in Prostate Cancer: An Update.
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Statins and ALS: the possible role of impaired LXR signaling.
Statins and cardioprotection - More than just lipid lowering?
Statins and the liver.
Statins and the Liver.
Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria.
Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence.
Statins impair glucose uptake in tumor cells.
Statins in acute coronary syndrome: very early initiation and benefits.
Statins in chronic kidney disease and kidney transplantation.
Statins in COPD: A Systematic Review.
Statins in the 21st century: end of the simple story?
Statins in the spectrum of neurologic disease.
Statins potently reduce the cytokine-mediated IL-6 release in SMC / MNC cocultures.
Statins' effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90? in human colorectal cancer.
Statins, cardiovascular disease, and drug safety.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The beneficial effects of statins in autoimmune disease therapy.
The effects of lipid-lowering agents on acute renal allograft rejection.
The Effects of Statin Therapy on the Human Airway.
The effects of statins on endothelium, inflammation and cardioprotection.
The role of HMGCR alternative splicing in statin efficacy.
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy.
The use of fluvastatin in cardiovascular risk management.
Therapeutic value of statins for vascular remodeling.
Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
[HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials]
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
[Inhibitors of HMG CoA reductase: new modes of action, new indications?]
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
[Regulatory Mechanisms and Practical Management in Vascular Calcification. Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment.]
[Statins and asthma].
Carotid Artery Diseases
Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors.
Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.
Carotid Stenosis
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
Cataract
Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits.
Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats.
On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Central Nervous System Diseases
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
Central Nervous System Neoplasms
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Cerebellar Ataxia
Statin-associated cerebellar ataxia. A Brazilian case series.
Cerebral Hemorrhage
HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage.
Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study.
Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats.
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits.
Cerebral Infarction
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Neuroprotection mediated by changes in the endothelial actin cytoskeleton.
Cerebrovascular Disorders
Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans.
Epigallocatechin-3-gallate (EGCG) inhibits 3-hydroxy-3-methylglutaryl-CoA reductase in the presence of glycerol.
Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats.
Simvastatin treatment in surgically induced brain injury in rats.
Statins and neuroprotection: a prescription to move the field forward.
Statins therapy: a review on conventional and novel formulation approaches.
The acute (cerebro)vascular effects of statins.
Cholangiocarcinoma
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.
Cholelithiasis
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids.
Cholestasis
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats.
Cholesterol Ester Storage Disease
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
Restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.
Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease.
Choriocarcinoma
Regulation by plasma lipoproteins of progesterone biosynthesis and 3-hydroxy-3-methyl glutaryl coenzyme a reductase activity in cultured human choriocarcinoma cells.
Choroidal Neovascularization
Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice.
Colitis
Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.
Colitis, Ulcerative
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Colonic Neoplasms
Cholesterol metabolism and colon cancer.
Early induction of LDL receptor gene expression by genistein in DLD-1 colon cancer cell line.
Effect of genistein on cholesterol metabolism-related genes in a colon cancer cell line.
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
Statins in the chemoprevention of colorectal cancer in established animal models of sporadic and colitis-associated cancer.
Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer.
Colorectal Neoplasms
Cardiovascular medication use and risk for colorectal cancer.
Current data with HMG-CoA reductase inhibitors (statins) for colorectal cancer prevention.
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor.
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
Expression of the low-density lipoprotein receptor, HMG-CoA reductase, and multidrug resistance (Mdr1) genes in colorectal carcinomas.
Gamma-tocopherol enhances apoptotic effects of lovastatin in human colorectal carcinoma cell line (HT29).
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice.
Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis.
Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study.
Statins and the colorectum: hope for chemoprevention?
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90? in human colorectal cancer.
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
Communicable Diseases
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
Confusion
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.
Connective Tissue Diseases
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy.
[Necrotizing myopathies: From genetic to acquired forms.]
Coronary Artery Disease
"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.
(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Addressing the spectrum of hypercholesterolemia.
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
Coding-sequence variants are associated with blood lipid levels in 14,473 Chinese.
Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease : The Problem of Under-Treatment.
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
Do statins prevent heart failure in patients after myocardial infarction?
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms.
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease: A Post Hoc Analysis of Data from a Prospective, Randomized, Double-Blind Study.
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.
Effect of pravastatin on plasma sterols and oxysterols in men.
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
Effect of statins on atherogenic serum amyloid A and ?1-antitrypsin low-density lipoprotein complexes.
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Effects of lovastatin and pravastatin on cognitive function in military aircrew.
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.
Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac rehabilitation.
Evaluation of the promoter polymorphism -911C>A in the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase gene with coronary artery disease risk and cholesterol levels in a population from Western India.
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.
Ezetimibe and Vascular Inflammation.
HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.
HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease.
HMG-CoA Reductase Inhibitors in Chronic Heart Failure : Potential Mechanisms of Benefit and Risk.
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: evidence for antigen-independent mechanisms?
HMG-CoA reductase inhibitors: a look back and a look ahead.
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy.
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy.
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.
Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors, as predicted by a decision analysis model.
Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic.
Low-density lipoprotein apheresis therapy during pregnancy.
Medical management of coronary artery disease revisited: the endothelial factor.
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Noncholesterol-lowering effects of statins.
Pathophysiology and treatment of lipid perturbation after cardiac transplantation.
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4.
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis.
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Provider adherence to clinical guidelines related to lipid-lowering medications.
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention.
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.
Role of circulating lipid abnormalities in chronic renal allograft rejection.
Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients.
Statins enhance clonal growth of late outgrowth endothelial progenitors and increase myocardial capillary density in the chronically ischemic heart.
Statins in stroke: prevention, protection and recovery.
Statins, cardiovascular disease, and drug safety.
The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.
The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
The effect of statin therapy on allergic patients with asthma.
The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.
The role of statins in heart failure.
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.
[Cardiologists and limitations of statins reimbursement]
[Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits]
[The impact HMG-CoA reductase inhibitors in the modification of the natural history of coronary artery disease]
[The impact HMG-CoA reductase inhibitors on the modification of the natural history of coronary artery disease]
Coronary Disease
8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease.
A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease.
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Aggressive statin therapy for acute coronary syndromes.
Antioxidative effects of statins.
Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels.
Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine.
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
CHD: a major burden in type 2 diabetes.
Clinical pharmacokinetics of fluvastatin.
Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
Cost-effectiveness of statins.
Debate: at what level of coronary heart disease risk should a statin be prescribed?
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
Effective use of statins to prevent coronary heart disease.
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Evaluation and management of lipid disorders.
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
HMG-CoA reductase inhibitors: issues in assessing their benefits in coronary heart disease.
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
Intensive statin therapy in acute coronary syndromes.
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Lipid and non-lipid effects of statins.
Lipid-lowering for prevention of coronary heart disease: what policy now?
Niacin or ezetimibe for patients with, or at risk of coronary heart disease.
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Optimal medical management of peripheral arterial disease.
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.
Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease.
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Reduction of serum LDL-C levels: a relationship to clinical benefits.
Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
Results of recent large cholesterol-lowering trials and implications for clinical management.
Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
Statin therapy in the elderly: does it make good clinical and economic sense?
Statin treatment and progression of atherosclerotic plaque burden.
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Statins for cardiovascular prevention according to different strategies: a cost analysis.
Statins for primary prevention: at what coronary risk is safety assured?
Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.
The management of cholesterol in coronary heart disease risk reduction.
What do the statins tell us?
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
[Combined therapy with cholestyramine and HMG-CoA reductase inhibitors in secondary prevention of coronary disease]
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin]
[HMG-CoA reductase inhibitors for prevention and treatment of coronary heart disease. Effective reduction of cardiac events and mortality]
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
[Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease]
[The role of cholesterol-lowering drugs in prevention of coronary heart disease]
Coronary Restenosis
Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis.
Coronary Stenosis
Positron emission tomography and the changing paradigm in coronary artery disease.
Cough
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Cystic Fibrosis
Mechanistic similarities between cultured cell models of cystic fibrosis and niemann-pick type C.
Death, Sudden, Cardiac
Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?
Dehydration
Effect of prolonged water stress on essential oil content, compositions and gene expression patterns of mono- and sesquiterpene synthesis in two oregano (Origanum vulgare L.) subspecies.
Role of phytosterols in drought stress tolerance in rice.
Delirium
Statins and delirium: is there a role?
Dementia
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up.
Non-atheroprotective effects of statins: a systematic review.
Risk factors for dementia in patients over 65 with diabetes.
Risk factors for dementia with type 2 diabetes mellitus among elderly people in China.
The Effect of HMG: CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study.
The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia.
Demyelinating Diseases
Tellurium causes dose-dependent coordinate down-regulation of myelin gene expression.
Dengue
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Dermatitis, Phototoxic
Pitavastatin, a new HMG-CoA reductase inhibitor, induces phototoxicity in human keratinocytes NCTC-2544 through the formation of benzophenanthridine-like photoproducts.
The phototoxicity of fluvastatin, an HMG-CoA reductase inhibitor, is mediated by the formation of a benzocarbazole-like photoproduct.
Dermatomyositis
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
[Pravastatin-induced dermatomyositis]
Diabetes Mellitus
Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis.
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease : The Problem of Under-Treatment.
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Efficacy and safety of statins in the treatment of diabetic dyslipidemia.
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes.
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Lipids and stroke: the opportunity of lipid-lowering treatment.
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins).
REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients.
Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
Diabetes Mellitus, Experimental
Influence of streptozotocin diabetes on intestinal 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the rat.
Diabetes Mellitus, Type 1
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes.
The protective effect of simvastatin against low dose streptozotocin induced type 1 diabetes in mice is independent of inhibition of HMG-CoA reductase.
Diabetes Mellitus, Type 2
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes.
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Dose-dependent effect of hydroxymethylglutaryl-coenzyme A reductase inhibitor on serum cholesterol with limited dietary restrictions: a case study.
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.
Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes.
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Lipids and stroke: the opportunity of lipid-lowering treatment.
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
Management of dyslipidemia in NIDDM.
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes.
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Should the insulin resistance syndrome be treated in the elderly?
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes.
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin.
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Diabetic Angiopathies
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Diabetic Nephropathies
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats.
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy.
Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies.
Renoprotective effects of combining ACE inhibitors and statins in experimental diabetic rats.
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Diabetic Neuropathies
Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy.
Diabetic Retinopathy
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins.
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy.
Drug Eruptions
Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
Pravastatin-induced lichenoid drug eruption.
Drug-Related Side Effects and Adverse Reactions
Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.
HMG-CoA reductase inhibitors and myotoxicity.
HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles.
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury.
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Dyskinesias
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
Dyslipidemias
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductase.
Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.
Are all statins the same?: focus on the efficacy and tolerability of pitavastatin.
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Chlorogenic acid-enriched extract from Eucommia ulmoides leaves inhibits hepatic lipid accumulation through regulation of cholesterol metabolism in HepG2 cells.
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD.
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Diabetes and metabolic syndrome (MS).
Dyslipidemia and coronary artery disease.
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients.
Dyslipidemias in diabetic patients. Is standard cholesterol treatment appropriate?
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Effects of prickly pear dried leaves, artichoke leaves, turmeric and garlic extracts, and their combinations on preventing dyslipidemia in rats.
Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and "essential" phospholipids.
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
Genetic Contribution of Variants near SORT1 and APOE on LDL Cholesterol Independent of Obesity in Children.
High Maternal Serum Estradiol Levels Induce Dyslipidemia in Human Newborns via a Hepatic HMGCR Estrogen Response Element.
Human proximal tubular epithelium actively secretes but does not retain rosuvastatin.
Implications of recent statin trials for primary care practice.
Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.
Inhibitory effects of IFN-gamma on HIV-1 replication in latently infected cells.
Interactions between grapefruit juice and cardiovascular drugs.
Investigations of statins in heart failure: inflammatory biomarkers and hormones.
Lipid-lowering medications for children and adolescents.
Low-density lipoprotein apheresis as a treatment option for hyperlipidemia.
Management of diabetic dyslipidemia: need for reappraisal of the goals.
Management of dyslipidemia in adults.
Managing dyslipidemia in chronic kidney disease.
Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
Myopathy associated with atorvastatin-ezetimibe combination therapy.
Optimizing cardiovascular outcomes in diabetes mellitus.
Pathogenesis and management of diabetic dyslipidemia.
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Pitavastatin: a new HMG-CoA reductase inhibitor.
Potential Correlation between Statins and Pulp Chamber Calcification.
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes.
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Rosuvastatin for the treatment of hypercholesterolemia.
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosuvastatin: a review of its effect on atherosclerosis.
Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
Severe Rhabdomyolysis Associated With Concurrent Use of Simvastatin and Sirolimus After Cisplatin-Based Chemotherapy in a Kidney Transplant Recipient.
Simvastatin evokes an unpredicted inhibition of ?-adrenoceptor-mediated vasodilatation in porcine coronary artery.
Statin use and cognitive changes in elderly patients with dementia.
Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
Statins in oncological research: from experimental studies to clinical practice.
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.
The interaction of fluvastatin and cyclosporin A in renal transplant patients.
The potential behavioral and economic impacts of widespread HMG-CoA reductase inhibitor (statin) use.
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
Therapeutic value of statins for vascular remodeling.
Treatment of Alport syndrome: beyond animal models.
Treatment of diabetic dyslipidemia.
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia.
Vascular disease and lipids in diabetes.
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
[Diabetes and multimetabolic syndrome]
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]
[Effect of the brand and generic medicine of pravastatin on dyslipidemia in rabbits fed a high cholesterol diet]
[Lipid-lowering therapy in the prevention of coronary heart disease]
[Statin pharmacokinetics]
[Statins in the management of acute coronary syndrome]
[The treatment of refractory hyperlipoproteinemias]
[Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance]
Encephalomyelitis
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Endometrial Neoplasms
Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.
Endometriosis
Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells.
Eosinophilia
Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia.
Ependymoma
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Epilepsy
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy.
Use of antiepileptic drugs and lipid-lowering agents in the United States.
Erectile Dysfunction
Comment: HMG-CoA reductase inhibitor-induced impotence.
HMG CoA Reductase Inhibitors and Impotence: Two Case Series from the Spanish and French Drug Monitoring Systems.
HMG-CoA reductase inhibitor-induced impotence.
Exanthema
Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors.
Eye Diseases
Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases.
Fatigue Syndrome, Chronic
Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis.
Fatty Liver
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase.
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Oxysterols and alcoholic liver disease.
Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.
Suppression of hepatic HMG-CoA reductase activity by beta-muricholic acid in mice fed a diet containing cholesterol and cholic acid.
Fatty Liver, Alcoholic
Protective effect of Codonopsis lanceolata root extract against alcoholic fatty liver in the rat.
Fetal Growth Retardation
[Effects of intrauterine growth restriction and high-fat diet on serum lipid and transcriptional levels of related hepatic genes in rats].
Fibrosarcoma
Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells.
Tissue selective drug delivery utilizing carrier-mediated transport systems.
Fragile X Syndrome
The genetics of mental retardation.
Gallstones
3-hydroxy-3-methylglutaryl coenzyme A reductase in human liver microsomes: active and inactive forms and cross-reactivity with antibody against rat liver enzyme.
Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice.
Antilithiasic effect of beta-cyclodextrin in LPN hamster: comparison with cholestyramine.
Biliary lipid synthesis and secretion in gallstone patients before and during treatment with chenodeoxycholic acid.
Cholesterol metabolism in human gallbladder mucosa: relationship to cholesterol gallstone disease and effects of chenodeoxycholic acid and ursodeoxycholic acid treatment.
Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse.
Cholesterol synthesis inhibitors in cholesterol gallstone disease.
Circulating markers for biosynthesis of cholesterol and bile acids are not depressed in asymptomatic gallstone subjects.
Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity.
Dietary cholesterol affects chenodeoxycholic acid action on biliary lipids.
Dissolution of cholesterol gallstones by bile acids in hamsters.
Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor.
Effect of chenodeoxycholic acid and phenobarbital on the rate-limiting enzymes of hepatic cholesterol and bile acid synthesis in patients with gallstones.
Effects of bezafibrate on hepatic cholesterol metabolism.
Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones.
Hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity in hamsters on a lithogenic diet.
Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid.
Hepatic cholesterol and bile acid synthesis in Japanese patients with cholesterol gallstones.
Hepatic cholesterol metabolism in obesity: activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Hepatic cholesterol metabolism in patients with cholesterol gallstones: enhanced intracellular transport of cholesterol.
Hepatic cholesterol metabolism in patients with gallstones.
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids.
Hepatic microsomal activities of cholesterol 7 alpha-hydroxylase and 3-hydroxy-3-methylglutaryl-CoA reductase in the prairie dog. An animal model for cholesterol gallstone disease.
Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Intrahepatic biliary cholesterol and phospholipid transport in humans: effect of obesity and cholesterol cholelithiasis.
Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid.
Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients.
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
Rowachol and ursodeoxycholic acid in hamsters with cholesterol gallstones.
Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile.
Successful dissolution of cholesterol gallstone during treatment with pravastatin.
Therapeutic Reflections In Cholesterol Homeostasis And Gallstone Disease. A Review.
Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.
Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
[Experimental study on hepatic HMG-CoA reductase activity in relation to the formation and dissolution of cholesterol gallstones (author's transl)]
Gastroesophageal Reflux
Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?
Glaucoma
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Glaucoma, Open-Angle
The Relationship Between Statin Use and Open-Angle Glaucoma.
Glioblastoma
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model.
HMGCR positively regulated the growth and migration of glioblastoma cells.
Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Glioma
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?
HMG CoA reductase inhibitors, NSAIDs and risk of glioma.
In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.
Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?
Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells.
Regulation of sterol synthesis and of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lipoproteins in glial cells in primary culture.
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Glomerulonephritis
Effect of simvastatin on proliferative nephritis and cell-cycle protein expression.
Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group.
Statins and progressive renal disease.
Glomerulonephritis, IGA
Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.
Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy.
Statins and progressive renal disease.
Glomerulonephritis, Membranous
Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
Glucose Intolerance
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Gene-nutrient interactions in G6PD-deficient subjects--implications for cardiovascular disease susceptibility.
Glucosephosphate Dehydrogenase Deficiency
Gene-nutrient interactions in G6PD-deficient subjects--implications for cardiovascular disease susceptibility.
Goiter
HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway.
Graft vs Host Disease
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.
The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.
Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Gynecomastia
Golf-inhibiting gynecomastia associated with atorvastatin therapy.
Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature.
Headache
Altitude-induced migraine headache secondary to pravastatin: case report.
Hearing Loss
Irreversible atorvastatin-associated hearing loss.
Hearing Loss, Sensorineural
Possible role of HMG-CoA reductase inhibitors for the treatment of sudden sensorineural hearing loss (SSHL).
Heart Diseases
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Development of thyroid follicular adenoma on simvastatin therapy.
HMG-CoA reductase inhibitors in the prevention of stroke.
Impact of statins on novel risk markers.
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region.
[Early statin treatment in acute coronary syndrome. Is this evidence-based?]
Heart Failure
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure.
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Do statins have a role in the management of diastolic dysfunction?
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms.
HMG-CoA Reductase Inhibitors in Chronic Heart Failure : Potential Mechanisms of Benefit and Risk.
Impact of Statin Therapy on Clinical Outcomes in Chronic Heart Failure Patients According to Beta-Blocker Use: Results of CIBIS II.
Inflammation in chronic heart failure.
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Potential autonomic nervous system effects of statins in heart failure.
Potential role of statins in the treatment of heart failure.
Provider adherence to clinical guidelines related to lipid-lowering medications.
Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease.
Simvastatin normalizes autonomic neural control in experimental heart failure.
Statin therapy for cardiac hypertrophy and heart failure.
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.
Statins and the myocardium.
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
The nutritional and metabolic support of heart failure in the intensive care unit.
The role of statin therapy in the management of cardiomyopathies.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Heart Failure, Systolic
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
Hemangioma, Cavernous, Central Nervous System
The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylation-dependent signalling pathway.
Hematologic Neoplasms
HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Hepatitis
Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.
Cholesterol-induced stimulation of postinflammatory liver fibrosis.
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
[A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors]
[Acute cholestatic hepatitis after atorvastatin reintroduction.]
Hepatitis C
Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
Dihydroquercetin: More than just an impurity?
Do statins reduce hepatitis C RNA titers during routine clinical use?
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin.
Hepatitis C, Chronic
Do statins reduce hepatitis C RNA titers during routine clinical use?
Hepatoblastoma
Growth requirements and expression of LDL receptor and HMG-CoA reductase in Hep G2 hepatoblastoma cells cultured in a chemically defined medium.
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma Hep G2.
The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells.
Herpes Zoster
Differential ACTH response of immunodetectable HMG CoA reductase and cytochromes P450(17 alpha) and P450(21) in guinea pig adrenal outer zone cell types, zona glomerulosa and zona fasciculata.
Histiocytoma, Malignant Fibrous
Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.
HIV Infections
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Huntington Disease
Cholesterol synthesis in cultured skin fibroblasts from patients with Huntington's disease.
Hyperalgesia
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice.
Hypercholesterolemia
'Muscle-sparing' statins: preclinical profiles and future clinical use.
3-Hydroxy-3-methylglutaryl coenzyme A reductase deregulation and age-related hypercholesterolemia: a new role for ROS.
3-Hydroxy-3-methylglutaryl coenzyme A reductase regulation by antioxidant compounds: new therapeutic tools for hypercholesterolemia?
3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia.
A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
A controlled trial of pravastatin vs probucol in the treatment of primary hypercholesterolemia.
A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.
A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway.
A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters.
A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
A review of current clinical findings with fluvastatin.
A Review on the use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis.
Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression.
Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Adverse effects of long-term exposure to bisphenol A during adulthood leading to hyperglycaemia and hypercholesterolemia in mice.
Age-Related Hypercholesterolemia and HMG-CoA Reductase Dysregulation: Sex Does Matter (A Gender Perspective).
An In Vitro and Molecular Informatics Study to Evaluate the Antioxidative and ?-hydroxy-?-methylglutaryl-CoA Reductase Inhibitory Property of Ficus virens Ait.
Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia.
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Astragalus polysaccharides lowers plasma cholesterol through mechanisms distinct from statins.
Atorvastatin affects TLR4 clustering via lipid raft modulation.
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels.
Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.
Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways.
Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia.
Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase.
Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
Blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia.
Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Caloric restrictions affect some factors involved in age-related hypercholesterolemia.
Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.
Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia.
Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis.
Cholesterol and bile acid synthesis during total parenteral nutrition with and without lipid emulsion in the rat.
Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients.
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.
Chronokinetics of Pravastatin Administered in the PM Compared with AM Dosing.
Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.
Colesevelam hydrochloride.
Collision-induced dissociation of the negative ions of simvastatin hydroxy acid and related species.
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Combination therapy in cholesterol reduction: focus on ezetimibe and statins.
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.
Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis.
Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.
Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization.
Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Diabetes and metabolic syndrome (MS).
Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis.
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution.
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
Disulfiram-associated hypercholesterolemia.
Diverse effects of statins on angiogenesis: new therapeutic avenues.
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin.
Early response of hyperlipidemic subjects to simvastatin.
Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Effect of HMG-CoA reductase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: comparison among CETP/TaqIB genotype subgroups.
Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study.
Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia.
Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patients.
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.
Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia.
Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits and cholesterol-fed rabbits.
Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group.
Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.
Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia.
Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
Efficacy and short-term effects of pravastatin, a potent inhibitor of HMG-Co A reductase, on hypercholesterolemia in climacteric women.
Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
Endothelium modulates contractile response to simvastatin in rat aorta.
Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet.
Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form.
Epigallocatechin-3-gallate (EGCG) inhibits 3-hydroxy-3-methylglutaryl-CoA reductase in the presence of glycerol.
Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia.
Ezetimibe + simvastatin (Merck/Schering-Plough).
Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase.
Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.
Fluvastatin: effects beyond cholesterol lowering.
Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.
Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin.
Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.
HMG CoA reductase inhibitors: new horizons in the management of hypercholesteremia. XIth Congress of the European Society of Cardiology. Nice, France, September 10-14, 1989.
HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis.
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
HMG-CoA reductase inhibitors for hypercholesterolemia.
HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia.
HMG-CoA reductase inhibitors: a look back and a look ahead.
HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia.
HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation.
Hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A reductase regulation in aged female rats.
Hypercholesterolemia of copper deficiency is linked to glutathione metabolism and regulation of hepatic HMG-CoA reductase.
Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study.
Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors.
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.
Increased rate of cholesterologenesis--a possible cause of hypercholesterolemia in experimental chronic renal failure in rats.
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Increased superoxide anion production by platelets in hypercholesterolemic patients.
Influence of cholesterol supply on cell growth and differentiation in cultured enterocytes (CaCo-2).
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity.
Inhibition of Rab1 GTPase and endoplasmic reticulum-to-Golgi trafficking underlies statin's toxicity in rat skeletal myofibers.
Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia.
Interaction of cytosine arabinoside and lovastatin in human leukemia cells.
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Involvement of interleukin-1 in lead nitrate-induced hypercholesterolemia in mice.
Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier.
Is there a role for the adrenals in the development of hypercholesterolemia in Zucker fatty rats?
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects -- a randomized crossover study, the first report from Thailand.
Lead nitrate-induced development of hypercholesterolemia in rats: sterol-independent gene regulation of hepatic enzymes responsible for cholesterol homeostasis.
Lipid-lowering medications.
Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia.
Long-term effects of pravastatin on serum lipid levels in elderly patients with hypercholesterolemia.
Long-term safety and efficacy profile of simvastatin.
Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia.
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
Lovastatin production: From molecular basis to industrial process optimization.
Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway.
Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro.
Low-density lipoprotein apheresis therapy during pregnancy.
Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
Management of hyperlipidemia: goals for the prevention of atherosclerosis.
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Mevalonate cascade and its regulation in cholesterol metabolism in different tissue in health and disease.
Modified HMG-CoA reductase and LDLr regulation is deeply involved in age-related hypercholesterolemia.
Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase gene expression by CuZn superoxide dismutase in human fibroblasts and HepG2 cells.
Modulation of hypercholesterolemia-induced alterations in apolipoprotein B and HMG-CoA reductase expression by selenium supplementation.
National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool.
New concepts of mechanisms of intestinal cholesterol absorption.
New drugs for treating hypercholesterolemia and other hyperlipidaemias--the HMG CoA reductase inhibitors.
New insights into the genetic regulation of intestinal cholesterol absorption.
Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.
Nutrition classics. Proceedings of the National Academy of Sciences of the United States of America, Volume 71, 1974: Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. By Michael S. Brown and Joseph L. Goldstein.
Omega-3 as well as caloric restriction prevent the age-related modifications of cholesterol metabolism.
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Opposing effects of dietary sugar and saturated fat on cardiovascular risk factors and glucose metabolism in mitochondrially impaired mice.
Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice.
Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.
Pharmacotherapy of dyslipidemia.
Photostability of pitavastatin-A novel HMG-CoA reductase inhibitor.
Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Plasma and thrombocyte levels of coenzyme Q10 in children with Smith-Lemli-Opitz syndrome (SLOS) and the influence of HMG-CoA reductase inhibitors.
Plasma lipoproteins and cholesterol metabolism in Yoshida rats: an animal model of spontaneous hyperlipemia.
Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
Pleiotropic effects of statins on the treatment of chronic periodontitis - a systematic review.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity.
Potential role of nonstatin cholesterol lowering agents.
Potential roles for statins in critically ill patients.
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Primary prevention: Do the very elderly require a different approach?
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.
Protective effect of arjunolic acid against atorvastatin induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways.
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects).
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis.
Regulation and degradation of HMGCo-A reductase.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia.
Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.
Role of statins in the treatment of multiple sclerosis.
Rosuvastatin for the treatment of hypercholesterolemia.
Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.
Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras.
Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
Simvastatin increases excitability in the hippocampus via a PI3 kinase-dependent mechanism.
Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3? phosphorylation.
Simvastatin inhibits glucose metabolism and legumain activity in human myotubes.
Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells.
Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia.
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation.
Statin mediated protection of the ischemic myocardium.
Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.
Statin Use in Prostate Cancer: An Update.
Statin-associated myopathy and its exacerbation with exercise.
Statins and renal diseases: from primary prevention to renal replacement therapy.
Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway.
Stimulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity by o,p'-DDD.
Structural mechanism for statin inhibition of HMG-CoA reductase.
Structure-Based Design and Screen of Novel Inhibitors for Class II 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase from Streptococcus Pneumoniae.
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Successful dissolution of cholesterol gallstone during treatment with pravastatin.
Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease.
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.
Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The antioxidant effect of lovastatin on phagocyte-induced DNA damage: implications for cancer prevention.
The beneficial effects of statins in autoimmune disease therapy.
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.
The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function.
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.
The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia.
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review.
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Therapeutic effects of ML-236B in primary hypercholesterolemia.
Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.
Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy.
Thyroid-Stimulating Hormone Decreases HMG-CoA Reductase Phosphorylation via AMP-Activated Protein Kinase in the liver.
Torcetrapib + atorvastatin (Pfizer).
Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin.
Treatment of hyperlipidemia in human renal disease.
Update on Statins: Hope for Osteoporotic Fracture Healing Treatment.
Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
[A comparative long-term trial of sodium cerivastatin, a new HMG-CoA reductase inhibitor, in patients presenting with primary hypercholesterolemia]
[Characteristics of a statine of the most recent generation]
[Cholesterol absorption as a target for the treatment of hypercholesterolemia]
[Combined therapy with cholestyramine and HMG-CoA reductase inhibitors in secondary prevention of coronary disease]
[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia]
[Diabetes and multimetabolic syndrome]
[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]
[Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]
[HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering]
[Hypolipidemic drugs--ileal Na+/bile acid cotransporter inhibitors (S-8921 etc)]
[Lipid status and basal steroid hormone level following 16 weeks of lovastatin therapy in primary hypercholesterolemia]
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
[New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors]
[New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis]
[Personal experience with lovastatin, a HMG-CoA reductase inhibitor (Mevacor, MSD) in the treatment of hypercholesterolemia]
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis]
[Statins: possibly more than just lowering of the lipid level]
[Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia]
[The effects of plasma cholesterol reduction on vasoconstriction due to sympathetic activation in patients with moderate primary hypercholesterolemia]
[The long-term effect of HMG-CoA reductase inhibitor to the hypercholesterolemia in the climacterium and its endocrinological change]
[Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up]
Hyperglycemia
Lipid partitioning after uninephrectomy.
Optimizing cardiovascular outcomes in diabetes mellitus.
The Effect of Statins on the No-Reflow Phenomenon: An Observational Study in Patients with Hyperglycemia before Primary Angioplasty.
Hyperhomocysteinemia
Fluvastatin ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: the antioxidative properties of fluvastatin.
The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
Hyperinsulinism
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Hexosamine Biosynthesis Impairs Insulin Action via a Cholesterolgenic Response.
Opposing effects of dietary sugar and saturated fat on cardiovascular risk factors and glucose metabolism in mitochondrially impaired mice.
The effects of insulin on plasma mevalonate concentrations in man.
Hyperkalemia
Hyperkalemia during treatment with HMG-CoA reductase inhibitor.
Hyperlipidemia, Familial Combined
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
Hyperlipidemias
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats.
A perinatal strategy to prevent coronary heart disease.
A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin.
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.
Are all statins the same?: focus on the efficacy and tolerability of pitavastatin.
Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
CE: Triglycerides: Do They Matter?
Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia.
Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins.
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
Do statins have a role in the management of diastolic dysfunction?
Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Drug treatment of combined hyperlipidemia.
Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression.
Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study.
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
Effect of geraniol, a plant derived monoterpene on lipids and lipid metabolizing enzymes in experimental hyperlipidemic hamsters.
Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients.
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Effect of in utero exposure of Toddy (coconut palm wine) on liver function and lipid metabolism in rat fetuses.
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia.
Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Effects of an HMG-CoA reductase inhibitor, pravastatin, and bile sequestering resin, cholestyramine, on plasma plant sterol levels in hypercholesterolemic subjects.
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia.
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Energy replacement using glucose does not increase postprandial lipemia after moderate intensity exercise.
Extract of Wax Gourd Peel Prevents High-Fat Diet-Induced Hyperlipidemia in C57BL/6 Mice via the Inhibition of the PPAR? Pathway.
Ezetimibe in Renal Transplant Patients with Hyperlipidemia Resistant to HMG-CoA Reductase Inhibitors.
Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells.
HMG CoA reductase inhibitors (statins) for dialysis patients.
HMG CoA reductase inhibitors and the skeleton: a comprehensive review.
HMG CoA reductase inhibitors for treatment of hyperlipidemia.
HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals.
HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia.
Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins.
Impact of prescription size on statin adherence and cholesterol levels.
Influence of large molecular polymeric pigments isolated from fermented Zijuan tea on the activity of key enzymes involved in lipid metabolism in rat.
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Kakkalide and irisolidone: HMG-CoA reductase inhibitors isolated from the flower of Pueraria thunbergiana.
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
Managed care trends in statin usage.
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions.
Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers.
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo.
Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
Pitavastatin: a new HMG-CoA reductase inhibitor.
Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review.
Pleiotropic effects of the HMG-CoA reductase inhibitors.
Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus.
Potential roles for statins in critically ill patients.
Prenatal exposure of an alcoholic beverage (Arrack) on fetal lipid metabolism in rats.
Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitric oxide formation in aged and ovariectomized rats.
Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats.
Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in taiwan.
Regulation of osteoclast differentiation by statins.
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Selected statins produce rapid spinal motor neuron loss in vitro.
Simvastatin (MK 733): an effective treatment for hypercholesterolemia.
Simvastatin protects osteoblast against H2O2-induced oxidative damage via inhibiting the upregulation of Nox4.
Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient.
Spiny keratoderma: a common under-reported dermatosis.
Statin therapy: not just used to lower cholesterol?
Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study.
Statins and liver toxicity: a meta-analysis.
Strategies for minimizing hyperlipidemia after cardiac transplantation.
The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
The effects of pravastatin on hyperlipidemia in renal transplant recipients.
The HMG-CoA Reductase Pathway, Statins and Angioprevention.
The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke.
The Relationship Between Statin Use and Open-Angle Glaucoma.
The spectrum of statin hepatotoxicity: Experience of the drug induced liver injury network.
Topical application of statin affects bone healing around implants.
Treatment of severe nephrotic syndrome.
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.
Use of antiepileptic drugs and lipid-lowering agents in the United States.
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause.
Vertical bone augmentation with fluvastatin in an injectable delivery system: a rat study.
[A case of drug-induced pneumonia possibly associated with simvastatin]
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias]
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin]
[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]
[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
[Mechanisms of statin nephroprotective actions]
[Pravastatin vs. probucol in the treatment of hypercholesterolemia. A double-blind study]
[Study on anti-hyperlipidemia mechanism of high frequency herb pairs by molecular docking method].
[Study on lipid-lowering traditional Chinese medicines based on pharmacophore technology and patent retrieval].
[Treatment of hyperlipidemia with HMG-CoA reductase inhibitors]
Hyperlipoproteinemia Type II
Abnormal induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase in leukocytes from subjects with heterozygous familial hypercholesterolemia.
Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia.
Biologically active low density lipoprotein in human peripheral lymph.
Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin.
Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins.
Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia.
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.
Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia.
Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia.
Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol.
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on corticosteroid metabolism in patients with heterozygous familial hypercholesterolemia.
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia.
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Metabolism of low-density lipoproteins by cultured hepatocytes from normal and homozygous familial hypercholesterolemic subjects.
Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
Nutrition classics. Proceedings of the National Academy of Sciences of the United States of America, Volume 71, 1974: Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. By Michael S. Brown and Joseph L. Goldstein.
Reappraisal of partial ileal bypass for the treatment of familial hypercholesterolemia.
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and the esterification of cholesterol in human long term lymphoid cell lines.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.
Restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.
Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.
Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.
Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.
Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatment.
The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.
The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.
The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia.
Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system.
Use of mutant fibroblasts in the analysis of the regulation of cholesterol metabolism in human cells.
[Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia]
[Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia]
[Familial hypercholesterolemia--intensive diet therapy combined with drug therapy]
[HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences]
[Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia]
Hyperlipoproteinemia Type III
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Hyperlipoproteinemias
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in the human gastrointestinal tract.
Chronic treatment with fluvastatin improves smooth muscle dilatory function in genetically determined hyperlipoproteinemia.
Comparison of different HMG-CoA reductase inhibitors.
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia.
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia.
Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment.
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
Hyperpigmentation
Artemisinic acid inhibits melanogenesis through downregulation of C/EBP ?-dependent expression of HMG-CoA reductase gene.
Hypersensitivity
Drug Allergies Documented in Electronic Health Records of a Large Healthcare System.
Pleiotropic phenotypes caused by an opal nonsense mutation in an essential gene encoding HMG-CoA reductase in fission yeast.
[Polymyositis induced or associated with lipid-lowering drugs: five cases]
Hypertension
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension.
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Effects of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on glucose tolerance in patients with essential hypertension.
Functional promoter polymorphisms govern differential expression of HMG-CoA reductase gene in mouse models of essential hypertension.
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway.
Neuroprotective and anti-inflammatory activities of atorvastatin in a rat chronic constriction injury model.
Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.
Post-transplant diabetes mellitus: risk reduction strategies in the elderly.
Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center.
Recent clinical trial highlights in hypertension.
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.
Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress.
Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.
Spiny keratoderma: a common under-reported dermatosis.
Sympathoinhibition by Atorvastatin in Hypertensive Patients.
The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia.
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
[Prevention of the manifestation of diabetes in the elderly in the presymptomatic stage]
[Simvastatin attenuates cardiovascular effects and oxidative stress induced by angiotensin II]
Hypertension, Pulmonary
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Emerging therapies for the treatment of pulmonary hypertension.
HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase.
Statins inhibit pulmonary artery smooth muscle cell proliferation by upregulation of HO-1 and p21(WAF1).
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Hypertriglyceridemia
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways.
Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors.
Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.
Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia.
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.
HMG-CoA reductase activity in the liver of rats with hereditary hypertriglyceridemia: effect of dietary fish oil.
Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Hypertriglyceridemia.
Insulin deficiency alters cellular cholesterol metabolism in murine macrophages.
Management of dyslipidemia in NIDDM.
Protective effect of arjunolic acid against atorvastatin induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways.
Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts.
The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients.
Treatment of hyperlipidemia in human renal disease.
[Goals and practical implementation of lipid therapy in coronary heart disease]
[Treatment for dyslipidemia--a strategy for the prevention of atherosclerosis].
Hypoalbuminemia
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductase.
Hypotension
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.
Hypothyroidism
HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism.
The effect of hypothyroidism and thyroxine replacement on hepatic and intestinal HMG-CoA reductase and ACAT activities and biliary lipids in the rat.
Hypoxia, Brain
Targeted drug delivery to treat pain and cerebral hypoxia.
Idiopathic Pulmonary Fibrosis
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Infarction, Middle Cerebral Artery
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion.
Infection
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis.
Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.
DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target.
Differential induction and suppression of potato 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in response to Phytophthora infestans and to its elicitor arachidonic acid.
Dihydroquercetin: More than just an impurity?
Effect of atovastatin treatment on porcine circovirus 2 infection in BALB/c mice.
Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters.
Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.
HMG CoA reductase is negatively associated with PCV2 infection and PCV2-induced apoptotic cell death.
HMGCR inhibits the early stage of PCV2 infection, while PKC enhances the infection at the late stage.
HmgR, a key enzyme in the mevalonate pathway for isoprenoid biosynthesis, is essential for growth of Listeria monocytogenes EGDe.
Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin.
Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.
Lipid Metabolism in Vascular Smooth Muscle Cells Infuenced by HCMV Infection.
Lipid-derived signals that discriminate wound- and pathogen-responsive isoprenoid pathways in plants: methyl jasmonate and the fungal elicitor arachidonic acid induce different 3-hydroxy-3-methylglutaryl-coenzyme A reductase genes and antimicrobial isoprenoids in Solanum tuberosum L.
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Regulation of HMG-CoA reductase activity in plants.
RhoA is activated during respiratory syncytial virus infection.
Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.
The effect of rosuvastatin in a murine model of influenza A infection.
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Infertility, Male
Loss of function of 3-hydroxy-3-methylglutaryl coenzyme A reductase 1 (HMG1) in Arabidopsis leads to dwarfing, early senescence and male sterility, and reduced sterol levels.
Inflammatory Bowel Diseases
Hypothalamic digoxin, hemispheric chemical dominance, and inflammatory bowel disease.
Influenza, Human
The effect of rosuvastatin in a murine model of influenza A infection.
Insulin Resistance
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes.
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.
Lipid partitioning after uninephrectomy.
Modified HMG-CoA reductase and LDLr regulation is deeply involved in age-related hypercholesterolemia.
New onset diabetes mellitus induced by statins: current evidence.
Optimizing cardiovascular outcomes in diabetes mellitus.
Should the insulin resistance syndrome be treated in the elderly?
Statins and diabetes risk: how real is it and what are the mechanisms?
The Effect of HMG-CoA Reductase Inhibitor on Insulin Resistance in Patients Undergoing Peritoneal Dialysis.
The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.
Intellectual Disability
The genetics of mental retardation.
Intermittent Claudication
Drug treatment of peripheral arterial disease in the elderly.
Peripheral arterial disease: a review of disease awareness and management.
Intracranial Hemorrhages
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Iron Overload
Iron overload potentiates diet-induced hypercholesterolemia and reduces liver PPAR-? expression in hamsters.
Irritable Bowel Syndrome
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Ischemic Attack, Transient
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Kidney Diseases
Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats.
Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease.
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Statins and progressive renal disease.
Kidney Failure, Chronic
Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.
Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.
HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.
Lovastatin has direct renal hemodynamic effects in a rodent model.
Kidney Neoplasms
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Leprosy
Indirect assay of beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients--a further probe into cholesterol metabolism.
Leukemia
Calcium ionophore treatment impairs the sterol-mediated suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 3-hydroxy-3-methylglutaryl-coenzyme A synthase, and farnesyl diphosphate synthetase.
Coamplification of 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in methotrexate-resistant human leukemia cell lines.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis in freshly isolated hairy cell leukemia cells.
Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo.
P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.
[Effects of simvastatin on PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1].
Leukemia, Erythroblastic, Acute
Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors.
Leukemia, Hairy Cell
Increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis in freshly isolated hairy cell leukemia cells.
Leukemia, Monocytic, Acute
[Effects of simvastatin on PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1].
Leukemia, Myeloid, Acute
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.
Statins induce lethal effects in acute myeloblastic lymphoma cells within 72 hours.
Leukostasis
CD11b+ bone marrow-derived monocytes are the major leukocyte subset responsible for retinal capillary leukostasis in experimental diabetes in mouse and express high levels of CCR5 in the circulation.
Lichen Planus
[Simvastatin-induced lichen planus pemphigoides]
Lipidoses
Effect of pravastatin, a HMG CoA reductase inhibitor, on blood lipids and aortic lipidosis in cholesterol-fed White Carneau pigeons.
Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine.
Lipodystrophy
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study.
Lipomatosis
Molecular biology of metabolic disease: defects in the regulation of enzymic activity.
Liver Cirrhosis
Cholesterol-induced stimulation of postinflammatory liver fibrosis.
Liver Diseases
Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease : A Retrospective Cohort Study.
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Liver Neoplasms
Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.
Liver Neoplasms, Experimental
Effect of assay temperature on the kinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in rat liver and Morris hepatoma 5123C.
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid.
Lung Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Lung Diseases, Interstitial
Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease.
Statins and Pulmonary Fibrosis: The Potential Role of NLRP3 Inflammasome Activation.
Lung Injury
[A case of drug-induced pneumonia possibly associated with simvastatin]
Lung Neoplasms
In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent.
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
Lupus Erythematosus, Systemic
Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
Lymphoma
Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Autophagy contributes to apoptosis in A20 and EL4 lymphoma cells treated with fluvastatin.
HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma.
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Lymphoma, B-Cell
Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease.
Lymphoma, Non-Hodgkin
HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Macular Degeneration
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study.
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Marek Disease
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Medulloblastoma
Cell-cycle gene expression in lovastatin-induced medulloblastoma apoptosis.
Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines.
Melanoma
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
Biphenylalkylacetylhydroquinone ethers suppress the proliferation of murine B16 melanoma cells.
Decrease of cholesterol in mouse melanoma causes secretion of lysosomal enzymes.
Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression.
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
Melanoma, Experimental
d-?-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells.
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Memory Disorders
Short-term memory loss associated with rosuvastatin.
Meningioma
Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.
Metabolic Diseases
High Maternal Serum Estradiol Levels Induce Dyslipidemia in Human Newborns via a Hepatic HMGCR Estrogen Response Element.
Mevalonate Kinase Deficiency
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured fibroblasts from patients with mevalonate kinase deficiency: differential response to lipid supplied by fetal bovine serum in tissue culture medium.
Clinical and biochemical phenotype in 11 patients with mevalonic aciduria.
Microvascular Angina
Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity.
Mitochondrial Myopathies
Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin.
Mucocutaneous Lymph Node Syndrome
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Multiple Myeloma
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
Statins Are Associated With Reduced Mortality in Multiple Myeloma.
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
[In vitro effects of mevastatin on the proliferation and apoptosis in human multiple myeloma cell line U266]
Multiple Sclerosis
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis.
Atorvastatin induces T cell anergy via phosphorylation of ERK1.
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis.
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy.
The Combination of Interferon-Beta and HMG-CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?
[Direct neuronal effects of statins]
Muscle Weakness
[Autoimmune myopathy associated with statin use].
Muscular Diseases
Adaptive immune response to therapy in hmgcr autoantibody myopathy.
Advances in serological diagnostics of inflammatory myopathies.
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study.
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Atorvastatin Metabolite Measurements as a Diagnostic Tool for Statin-Induced Myopathy.
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy.
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.
Benefits and risks of simvastatin in patients with familial hypercholesterolaemia.
Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.
Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
Clinical pharmacokinetics and practical applications of simvastatin.
Clinical pharmacokinetics of pravastatin.
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Dermatomyositis and drugs.
Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats.
Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent.
Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats.
Effect of simvastatin on passive strain-induced skeletal muscle injury in rats.
Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.
Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method.
Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.
High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults.
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients.
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.
Identifying statin-associated autoimmune necrotizing myopathy.
Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts.
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts.
Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine.
Large-scale chemical dissection of mitochondrial function.
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle.
Mechanism underlying long-term regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase during L6 myoblast differentiation.
Myopathy associated with chronic orlistat consumption: a case report.
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.